To assess the clinical significance of FHOD1 and FMNL1 expression in intestinal-type gastric cancer, we studied the correlation between clinical variables such as tumor size, stage and tumor location as well as molecular tumor subtypes (TP53, MMR and EBV status) and FHOD1 and FMNL1 expression. The gene discussed is TP53; the disease is gastric cancer.